a r t i c l e s to therapy using antibodies to VEGF. We hypothesized that tumors achieve this resistance through secreted factors. We addressed this issue by profiling tumor cell-secreted proteins using our wellcharacterized tumor models that are resistant (EL4) or sensitive (Tib-6) to treatment with antibodies to VEGF [11] [12] [13] . Our analysis revealed that the most abundantly secreted protein in the conditioned medium of EL4 cells, as well as the most differentially expressed cytokine compared to the sensitive cell line, was IL-17A, the canonical cytokine of the T H 17 subset of T cells (hereafter referred to as IL-17) (Fig. 1a,b) .
Prompted by these findings, we investigated the role of IL-17 in the modulation of the tumor response to treatment with antibodies to VEGF. IL-17, also known as CTLA8, is a proinflammatory cytokine that has been implicated in autoimmunity, inflammation and cancer 14 . To determine whether IL-17 affects the tumor-associated stromal-cell phenotype, we performed an in vivo screen of circulating secreted factors in tumor-bearing mice, as assessment of the multiple potential target cell types for IL-17 needs to be done in an intact animal 15 . As the in vitro results for IL-17 production by EL4 cells were recapitulated in vivo in tumor-bearing animals ( Fig. 1c) , we next examined the amounts of proinflammatory factors known to be induced by IL-17. We found that the amounts of G-CSF and IL-6 were similarly increased in tumor-bearing mice (Fig. 1c) , whereas the amounts of other IL-17-inducible factors, such as chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2, tumor necrosis factor-α (TNF-α) and IL-1β, were unchanged compared to tumor-naive mice (data not shown). Notably, EL4 tumor-bearing mice also had an increased amount of prokineticin 2 (Bv8, also called PROK2) (Fig. 1c) , a G-CSF-inducible angiogenic factor 16 that has been previously reported to mediate tumor refractoriness to VEGF blockade 17 . Administration of a neutralizing antibody to IL-17A in vivo significantly reduced the amounts of G-CSF, IL-6 and VEGF and lowered the amount of Bv8 in the circulation of tumor-bearing mice (Fig. 1c) . That treatment with the IL-17-specific antibody did not markedly change the amount of IL-17 ( Fig. 1c) probably reflects the inability of the assay to distinguish free from antibody-bound IL-17. Addition of this antibody to IL-17 inhibited ~70% of EL4 cell-induced G-CSF secretion by fibroblasts in coculture (Supplementary Fig. 1c ), confirming its neutralizing activity against IL-17. In contrast, antibody neutralization of other known G-CSF inducers, including TNF-α and IL-1β, both of which are secreted by the refractory tumor, had little or no effect on the circulating concentration of G-CSF ( Supplementary  Fig. 1c ). Together these data suggest that IL-17 has a dominant role in regulating the systemic amounts of soluble factors involved in inflammation and angiogenesis.
We next looked for evidence of IL-17 involvement in 23 advancedstage human colorectal adenocarcinoma specimens. We found that the number of IL-17 immunopositive tumor-infiltrating T H 17 40 ,000 EL4 a Tib-6 30,000 20,000 10,000 1,000 Concentration (pg ml npg a r t i c l e s lymphocytes correlated significantly with the number of tumorassociated Bv8-expressing neutrophils, particularly surrounding the tumor margins ( Fig. 1d and Supplementary Fig. 1a,b) . This result suggests a functional link between these two cell types, whose influx into tumors is associated with poor outcome in colorectal cancer as well as in hepatocellular and lung carcinomas 10 .
Refractoriness to VEGF-specific antibodies requires IL-17
To further investigate the role of IL-17 in the tumor microenvironment in vivo, we used three experimental systems (Fig. 2) . First, we used the EL4 cell line in a syngeneic transplant system. This cell line is resistant to treatment with antibodies to VEGF and, similarly to T H 17 cells, expresses both IL-17A and the closely related cytokine IL-17F (Supplementary Fig. 1d ). We treated EL4 tumor-bearing mice with antibodies to VEGF alone and in combination with an IL-17A-neutralizing antibody. Second, we implanted EL4 cells into C57BL/6 (wild type, WT) and IL-17R-deficient mice (Il17rc −/− , hereafter referred to as knockout mice). IL-17RA and IL-17RC form a heterodimeric receptor complex that is required for IL-17 signaling in humans and mice, and knockout mice are nonresponsive to IL-17 signaling inputs18. Third, we used an allograft model in which we tested the effects of IL-17A expression in tumor cells (Tib-6) that are sensitive to treatment with antibodies to VEGF. Treatment of EL4 tumor-bearing mice with a monoclonal antibody to IL-17A in combination with antibodies to VEGF improved the response to the VEGF-specific antibodies and inhibited tumor growth by ~50% compared to mice treated with an antibody specific for an irrelevant protein, ragweed, a control. Inhibition of IL-17A signaling without VEGF antibody treatment had only a slight effect on tumor growth (Fig. 2a,b) . In the second experimental system, we tested the growth and drug response of EL4 tumors in WT mice compared to knockout littermates (Fig. 2c,d ). In the control treatment groups without VEGF antibody treatment, EL4 tumor volume was reduced by ~50% in knockout mice compared to WT mice, suggesting that IL-17 signaling in the host stroma has a role in tumor growth, a result which is potentially related to our finding that VEGF expression in EL4-tumor bearing mice is IL-17 dependent (Fig. 1c) . Notably, IL-17R deficiency resulted in an almost 80% tumor growth inhibition by treatment with antibodies to VEGF compared to the modest effects such antibodies had in WT mice. The loss of IL-17 signaling in host stromal cells had a more marked effect on tumor growth in this genetic mouse model compared to pharmacologic neutralization of IL-17A, potentially because of insufficient in vivo neutralization of heterodimeric IL-17A and IL-17F and homodimeric IL-17F species by antibodies to IL-17A. To address this possibility, we tested an IL-17F-neutralizing antibody, both alone and in combination with antibodies to IL-17A, in EL4 tumor-bearing mice. The combination of the two types of antibodies did not offer further attenuation of tumor growth compared to antibodies to IL-17A only (Supplementary Fig. 1d,e) , suggesting that IL-17F has little effect on tumor growth. Therefore, the greater inhibition of tumor growth in the genetic model likely reflects a more complete or persistent inhibition of IL-17R signaling than that achieved through pharmacological means. Taken together these data suggest that tumor growth and the antitumor effects of VEGF blockade are dependent on IL-17 signaling within the host tumor microenvironment. Notably, these effects are dependent on Fig. 1f ).
We confirmed that our refractory model was truly VEGF independent in dose-response studies using VEGF-specific antibodies that showed saturation of antitumor efficacy with the lowest dose of antibody tested (5 mg per kg body weight) and by ELISA assays demonstrating that the amounts of VEGF-specific antibody were in excess of those of its target ligand within the tumor (Supplementary Fig. 2a,b) . It is also unlikely that IL-17 directly induces VEGF systemically, as naive mice treated with an IL-17A-specific antibody did not have markedly altered amounts of VEGF and VEGF amounts did not differ significantly between EL4 tumor-bearing WT and knockout mice ( Supplementary Fig. 2c,d ). However, a direct role of IL-17 in facilitating tumor angiogenesis was suggested by in vitro assays ( Supplementary Fig. 2e ), further implicating a direct angiogenic function for IL-17.
To further test the role of IL-17 in mediating tumor resistance to VEGF inhibition, we transduced a treatment-sensitive tumor cell line, Tib-6, with mouse IL-17A (generating Tib-6-IL-17 cells) or with neomycin (generating Tib-6-neo cells) and tested the response of the transduced cells to treatment with antibodies to VEGF when implanted into immunodeficient (nu/nu) recipient mice. Tib-6-IL-17-tumor bearing mice had markedly higher amounts of both circulating and tumor-localized IL-17A compared to Tib-6-neo-tumor bearing mice (data not shown). We also detected higher amounts of G-CSF in Tib-6-IL-17 tumors than in Tib-6-neo-tumors, and Tib-6-IL-17 tumors recruited more CD11b + Gr1 + cells than did Tib-6-neo tumors (Fig. 2f) . Although Tib-6-IL-17 tumors did not show a substantial increase in tumor growth rate compared to Tib-6-neo tumors ( Supplementary Fig. 1g ), they were significantly more resistant to treatment with antibodies to VEGF, as assessed using four independent stable Tib-6-IL-17 cell lines compared to two Tib-6-neo control cell lines (Fig. 2e) . These gain-of-function data in nu/nu mice indicate that IL-17 effector function can occur independently of additional inputs from T cells, suggesting that IL-17 function is both necessary and sufficient to mediate a proinflammatory network that drives therapeutic resistance to antibodies to VEGF.
IL-17 mediates CD11b + Gr1 + cell mobilization and recruitment To investigate the role of IL-17 signaling in the tumor microenvironment, we sought to better characterize differences in the tumor milieu in WT compared to Il17rc −/− hosts. Serum concentrations of IL-17A were similarly elevated in WT and knockout mice bearing EL4 tumors compared to tumor-naive mice (Fig. 3a,b) . We screened known IL-17A-inducible proinflammatory factors and found significant increases in the amounts of only G-CSF and IL-6 in WT tumor-bearing compared to naïve mice (Fig. 3a) . In contrast, the serum concentration of G-CSF was not elevated in KO tumor-bearing compared to naïve mice (Fig. 3b) , providing further evidence that IL-17 signaling to the host stroma is required for G-CSF induction in vivo. Treatment with antibodies to VEGF did not change the serum concentrations of IL-17A, G-CSF or IL-6 in tumor-bearing WT or KO mice (Fig. 3b) . On the basis of these results, we postulate that IL-17 mediates systemic inflammation through paracrine mechanisms. Notably, the serum concentrations of monocyte chemoattractants, including CCL2, CCL3, CCL4 and CCL5, remained relatively unchanged between WT and knockout tumor-bearing mice ( Supplementary  Fig. 3a) . Likewise, the amounts of these factors were not induced in the IL-17 gain-of-function tumor model (Supplementary Fig. 3b ).
These results suggest that IL-17 does not elicit a specific monocytic proinflammatory program within the tumor microenvironment and that monocytes may not be the primary drivers of treatment refractoriness to VEGF-specific antibodies.
G-CSF is a principal regulator of granulopoiesis and has a key role in neutrophil mobilization from the bone marrow in response to a variety of environmental stresses 19, 20 . It is also known to mobilize immature myeloid cells, including precursors of granulocytes, macrophages and dendritic cells, that express both CD11b and Gr1. Despite this cell type and functional heterogeneity, this cell population is frequently referred to collectively as myeloid-derived suppressor cells (MDSCs). Consistent with effects on G-CSF serum concentrations, circulating concentrations of CD11b + Gr1 + cells were likewise elevated threefold in WT tumor-bearing mice compared to knockout tumorbearing hosts and tumor-naive mice (Fig. 3c,d) . Furthermore, the numbers of tumor-infiltrating CD11b + Gr1 + cells were significantly lower in knockout compared to WT hosts, as assesed by flow cytometry and immunofluorescent staining of tumor sections (Fig. 3d,e ). There were no statistically significant differences in the number of F4/80 + tumor-associated macrophages (Supplementary Fig. 3c ).
Within tumors of WT mice, we found that the CD11b + Gr1 + population represented a granulocytic CD11b + Gr1 hi MDSC population that was negative for the F4/80 + macrophage marker, whereas a cell population with intermediate Gr1 + staining intensity was characterized by F4/80 −/lo expression, and CD11b + Gr1 lo/− cells were predominantly F4/80 + macrophages (Supplementary Fig. 4a ). The CD11b + Gr1 hi population in the spleen and bone marrow was reduced in tumorbearing knockout compared to WT mice ( Supplementary Fig. 4c,d) , suggesting a role for IL-17 paracrine signaling in the maintenance and development of these immune-suppressive cells.
To test the requirement for G-CSF in mediating treatment refractoriness to antibodies to VEGF, we implanted the resistant EL4 cell line into syngeneic G-CSF receptor (G-CSFR) knockout mice (Csf3r −/− , hereafter referred to as G-CSFR knockout mice), in which all stromal host cells are deficient in G-CSF signaling. We observed that although G-CSF signaling did not seem to have a major impact on the growth of EL4 tumors, this signaling axis was indeed necessary in mediating tumor refractoriness to treatment with antibodies to VEGF, and was also necessary for CD11b + Gr1 + cell mobilization from the bone marrow and recruitment to the tumor microenvironment (Fig. 3f) . Together these data demonstrate the requirement for an IL-17-G-CSF signaling cascade in mediating resistance to antibodies to VEGF through the mobilization and recruitment of CD11b + Gr1 + cells to the tumor microenvironment.
IL-17 regulates immature myeloid cell effector function
Because CD11b + Gr1 + immature myeloid cells are known to drive tumor progression through immunosuppression and tumor angiogenesis (reviewed in refs. 21,22), we tested whether loss of IL-17 signaling affected these effector functions. To address this question, we first tested the ability of these cells to suppress T cell proliferation. The immunosuppressive function of CD11b + Gr1 + cells isolated from WT tumors was readily apparent but was missing from the same cells isolated from knockout hosts (Fig. 4a) . To get a more complete picture of IL-17-dependent effector functions, we performed gene expression profiling of CD11b + Gr1 + cells isolated from tumors of WT and knockout littermates. We found that loss of IL-17 signaling correlated with decreased expression of effector genes, including those encoding the proangiogenic factor Bv8, metalloprotease-9 (MMP-9) and the inflammation and cancer-promoting factors S100A8 and S100A9 a r t i c l e s (low-molecular weight calcium-binding proteins that have been implicated in MDSC recruitment and enhancement of MDSC activity 23 ) (Fig. 4b) . Using quantitative RT-PCR (qRT-PCR), we confirmed that expression of these effector genes was dependent on IL-17 signaling but was not affected by treatment with antibodies to VEGF (Fig. 4b) , suggesting a role for IL-17 signaling in the regulation of CD11b + Gr1 + effector function.
To further delineate the functional contribution of CD11b + Gr1 hi F4/80 − granulocytic MDSCs and CD11b + Gr1 lo/− F4/80 + tumor-associated macrophages (TAMs) in the tumor microenvironment, we performed whole-genome expression analysis of these myeloid subpopulations in WT and Il17rc knockout tumor-bearing hosts (Supplementary Fig. 4b) . Mannose receptor C type 1 (MRC1), a monocytic marker, has been previously shown to be enriched in the CD11b + Gr1 lo/− F4/80 + TAM population 24 , and we confirmed this finding. Among other genes that have been reported to have immune-suppressive functions, the expression of inducible nitric oxide synthase (iNOS, also known as NOS2) was higher in granulocytic MDSCs and was dependent on intact IL-17 signaling in the tumor microenvironment, whereas arginase was more highly expressed in the CD11b + Gr1 lo/− F4/80 + TAM subset. Furthermore, we found expression of TGF-β1, IL-10, GAL9 (also known as LGALS9) and ADAM17, which have all been reported to effectuate MDSC immune-suppressive functions, to be more prevalent in the TAM subset ( Supplementary  Fig. 4b) . Therefore, loss of IL-17 signaling results in attenuation of CD11b + Gr1 + cell recruitment as well as of the T cell-inhibition function of CD11b + Gr1 + cells and effector gene expression in these cells, allowing for the restoration of tumor sensitivity to VEGF blockade.
We further investigated the effects of IL-17 signaling on the tumor vasculature, as assessed by immunohistochemical detection of a Treatment with antibodies to VEGF or control antibodies to ragweed was initiated 48 h after tumor inoculation. Right, quantification of the number of CD11b + Gr1 + cells entering the circulation (top) and those infiltrating the tumor (bottom) in tumor-bearing WT compared to G-CSFR knockout hosts as determined by flow cytometric analysis. All data are shown as the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005 by Student's t test. a r t i c l e s pan-endothelial marker antigen, MECA-32 (mouse endothelial cell antigen, clone 32); we also evaluated vessel maturation by immunofluorescent costaining for the endothelial cell adhesion junction protein PECAM-1 (also known as CD31) and desmin, a marker for pericytes (a vasculature-support cell type). Mean vessel density, quantified as immunopositivity for MECA-32, was significantly lower in tumors established in knockout as compared to WT hosts either with or without VEGF-specific antibody treatment (Fig. 4c) . Notably, the percentage of pericyte-associated mature tumor vessels was greater after treatment with antibodies to VEGF in both WT and knockout hosts, consistent with the notion that VEGF blockade is efficient at pruning immature vessels and that IL-17 signaling has no significant effect on this process (Fig. 4d) . Together these data suggest a role for IL-17 in modulating the tumor vasculature by directing the effector function of CD11b + Gr1 + cells independently of VEGF.
Tumor-associated fibroblasts are activated by IL-17
Ex vivo profiling of secreted proteins from FACS-isolated GFP + EL4 tumor cells and host stromal cells revealed that the stromal compartment is the primary source of major proinflammatory cytokines (Fig. 5a) . To identify the stromal cell type responsible for proinflammatory cytokine production, we used platelet-derived growth factor receptor-α (PDGFR-α) as a cell-surface marker for sorting tumorassociated fibroblasts (TAFs), as this protein was recently reported to be expressed by TAFs in a number of tumor models 25 . PDGFR-α-positive cells also expressed additional TAF markers, including vimentin and smooth muscle actin (SMA), as detected by immunofluorescence; these cells also expressed fibroblast growth factor receptor-1 (FGFR1) but did not express myeloid lineage markers, including CXCR4 and MRC1, confirming the purity the sorted TAF cells (Supplementary Fig. 5a,b) . We next investigated the relative levels of cytokine and chemokine secretion by TAFs, tumor-associated CD11b + Gr1 + MDSCs and nongranulocytic CD11b + Gr1 − myeloid lineage cells. We found higher levels of cytokine secretion by TAFs as compared to the other tumorinfiltrating myeloid cell types (Fig. 5b) . Furthermore, cytokine analysis of freshly isolated TAFs from EL4 tumors in both WT and knockout recipients revealed reduced expression of G-CSF, IL-6 and granulocyte macrophage colony-stimulating factor (GM-CSF) in knockout TAFs, a r t i c l e s whereas the expression of VEGF was not different (Fig. 5c) ; in fact, VEGF expression was not affected by IL-17 signaling in any of the stromal cell types studied (Supplementary Fig. 3d ). Together these data support the notion that IL-17 signaling in TAFs controls a network of proinflammatory cytokines in the tumor milieu. The proinflammatory cytokines IL-17A and IL-17F have a high degree of sequence similarity and share many biological properties 14 . In an ex vivo setting, WT but not knockout TAFs could be further stimulated by IL-17A or IL-17F to express proinflammatory cytokines such as G-CSF and GM-CSF (Fig. 5d) . We conclude that the paracrine signaling function of IL-17 is necessary and sufficient for promoting phenotypic changes in fibroblasts within the tumor microenvironment.
IL-17A-IL-17F activation of target cells requires activation of the intracellular NF-κB, mitogen-activated protein kinase (MAPK) and C/EBP (also called CEBPA) signaling pathways to induce the expression of soluble factors, including G-CSF 14 . We therefore investigated whether these and additional intracellular signaling pathways were activated in TAFs in response to IL-17. Using a panel of signalingpathway inhibitors, we found that MEK (also called MAP2K1) and NF-κB signaling are required for IL-17-induced G-CSF expression, as indicated by a reduction of G-CSF expression in fibroblasts treated with either of two different MEK inhibitors (PD98059 and GDC-0973) or with an NF-κB pathway inhibitor (Bay11-7082) but not with inhibitors targeting the phosphatidylinositide 3-kinase (PI3K) or p38 MAPK pathways (Fig. 5e) . Together these data indicate that IL-17 is capable of inducing proinflammatory cytokines such as G-CSF in TAFs through MAPK and NF-κB signaling.
T H 17 cells mediate the response to VEGF-specific antibodies IL-17 is produced by the T H 17 subset of CD4 + and CD8 + T cells (Tc17 cells) [26] [27] [28] . Because the infiltration of T H 17 cells is associated with poor prognosis in human lung and colorectal cancers [29] [30] [31] , we sought to test the effect of tumor-infiltrating T H 17 cells in response to treatment with antibodies to VEGF in syngeneic mouse lung and colon cancer models. We observed a significant decrease in tumor burden in Lewis lung carcinoma (LLC)-bearing Il17rc −/− compared to WT littermates after treatment with antibodies to VEGF (Fig. 6a) .
In a lung orthotopic model in WT mice, we observed that treatment with a combination of VEGF-specific and IL-17AF-specific antibodies significantly reduced LLC luc+ (luciferase-expressing LLC) tumor burden compared to treatment with a VEGF-specific antibody alone (P < 0.05) (Supplementary Fig. 5c,d) . Likewise, growth of a colorectal tumor, CT-26, was significantly reduced in syngeneic mice when treated with antibodies to IL-17 and VEGF in combination as compared to treatment with antibodies to VEGF alone (Fig. 6a) .
We initially observed that the percentage of LLC tumor-infiltrating CD3 + T cells did not differ between WT and knockout hosts (1.24% ± 0.18% (mean ± s.e.m.) and 1.28% ± 0.22% of live tumor cells, respectively). However, consistent with recent reports indicating that anti-angiogenic therapies can increase tumor lymphocyte infiltration [32] [33] [34] , we found that treatment with antibodies to VEGF , all of which were used at 10 µM except for Bay11-7082 and GDC-0973, which were used at 1 µM) or vehicle (DMSO) for 30 min followed by the addition of purified IL-17A (100 ng ml −1 ) or IL-17F (200 ng ml −1 ) for 4 h. Representative assays from two independent cohorts run in triplicates are shown, and the data are shown as the mean ± s.e.m. *P < 0.05 by Student's t test.
a r t i c l e s increased the numbers of both tumor-infiltrating CD4 + and CD8 + cells in WT hosts, although there were tenfold higher numbers of CD4 + T cells compared to CD8 + T cells (Fig. 6b,c) . Although both of these mature T cell subpopulations are known to express IL-17, IL-17 expression was restricted to CD4 + cells in the LLC tumors (Fig. 6b,c and Supplementary Fig. 6a ). All IL-17 + CD4 + cells in LLC tumors also expressed IL-22 (Fig. 6b) , a hallmark cytokine for mature and terminally differentiated T H 17 cells 35 . We observed an increase in the IL-17 + IL-22 + CD4 + population in LLC tumors in both WT and knockout hosts (Fig. 6c) after treatment with antibodies to VEGF. The increased prevalence of these tumor-infiltrating lymphocytes (TILs) in WT hosts treated with antibodies to VEGF coincided with increased amounts of both IL-17 and G-CSF in the tumor microenvironment, as well as with increased recruitment of CD11b + Gr1 + myeloid cells (Fig. 6d) . Reduced recruitment of CD11b + Gr1 + cells in knockout compared to WT hosts in response to treatment with antibodies to VEGF corresponded to significant increases in CD4 + and CD8 + cell activation (P < 0.05), as well as to increases in the number of tumor-infiltrating T H 1 and interferon-γ (IFN-γ) + CD8 + T cells (P < 0.05) (Supplementary Fig. 6b-d ). Together these data suggest an additional role for IL-17 in the suppression of antitumor T cell activity after treatment with antibodies to VEGF, probably through the recruitment of immune-suppressive CD11b + Gr1 + cells. Furthermore, the numbers of TAMs, including those defined as proangiogenic (MRC1 hi CD11c − )) or angiostatic (MRC1 lo CD11c + ) 24 , were not significantly affected by IL-17 signaling within the tumor microenvironment ( Supplementary Fig. 6e ), indicating that these myeloid cell populations may not be a major contributor to the phenotype of refractoriness to VEGF-specific antibody treatment. Recent studies have suggested that IL-17 has a role in promoting tumor angiogenesis 36, 37 , although most of these studies were performed with recombinant IL-17 protein or retroviral transduction of the IL-17 gene into tumors. We therefore studied the effect of endogenous tumorinfiltrating T H 17 cells on the tumor vasculature in our syngeneic LLC tumor model, comparing Il17rc knockout to WT hosts. We found that the presence of the angiogenic factor Bv8 within tumors depended on IL-17 signaling and that VEGF-specific antibody-mediated depletion of tumor-associated endothelial cells was enhanced in knockout hosts (Fig. 6d,e ), indicating that endogenous T H 17 cells can promote persistent angiogenesis in the face of VEGF blockade. Pharmacological inhibition of IL-17 and Bv8 in combination produced no added effect compared to inhibition of either alone (Supplementary Fig. 7) , npg a r t i c l e s suggesting that these two molecules act in a linear pathway in vivo. In summary, our data provide evidence for the requirement of tumorinfiltrating T H 17 cells and IL-17 signaling within the host microenvironment in promoting expression of G-CSF and recruitment of immune-suppressive and proangiogenic CD11b + Gr + cells, thereby mediating resistance to VEGF-specific antibody therapy.
DISCUSSION
Here we demonstrate that tumor-infiltrating T H 17 cells and an intact IL-17 signaling pathway in the tumor microenvironment are responsible for mediating resistance to the anti-angiogenic and antitumor effects of VEGF blockade across several tumor types. IL-17 has a role in promoting a proinflammatory tumor microenvironment by inducing cytokine expression from TAFs, most notably G-CSF. G-CSF is crucial for the mobilization and recruitment of CD11b + Gr1 + myeloid cells to the tumor microenvironment that are capable of promoting VEGF-independent tumorigenesis. In addition, IL-17 enhances the proangiogenic function of these bone marrow-derived cells through expression of VEGF and Bv8, as expression of these two factors is attenuated in Il17rc −/− tumor-bearing mice. We further demonstrate a strong correlation between tumor infiltration of Bv8-expressing polymorphonuclear granulocytes and T H 17 cells in human colorectal cancer, both of which are features of poor clinical outcome, indicating the relevance of our findings to human disease. Taken together, these findings demonstrate the role of adaptive immunity in mediating resistance to VEGF-specific antibody therapy. Previous studies investigating tumor resistance to anti-angiogenic therapies have identified potential resistance mechanisms, including the recruitment of myeloid-derived suppressor cells and a role for tumor-associated fibroblasts in the expression of resistancepromoting factors (reviewed in ref. 38 ). This previous work raised the question of how interactions between the tumor and the normal host stroma promote resistance to VEGF blockade, leading us to uncover a crucial role for T H 17 cells and their canonical cytokine, IL-17, in mediating this process by eliciting G-CSF-dependent inflammation. Indeed, the tumor-suppressive effects of VEGF-specific antibodies in IL-17RC-deficient mice were largely recapitulated in G-CSFRdeficient mice, underscoring the importance of the IL-17-G-CSF signaling axis in resistance to VEGF blockade. Notably, we found that providing IL-17 to the tumor milieu was sufficient to produce resistance in a sensitive tumor type (Tib-6) in nu/nu mice, indicating that the effects of IL-17 on drug resistance do not require assistance from other T cell subsets such as T H 1 or cytotoxic T cells.
Abnormal myelopoiesis and tumor recruitment of immature myeloid cells is a common feature of tumor progression, although additional factors within the tumor microenvironment may be necessary for activating the immunosuppressive function of CD11b + Gr1 + MDSCs 21 . Our data show greatly impaired expression of tumor-and vasculature-promoting factors in IL-17RC − MDSCs compared to IL-17RC + MDSCs. Therefore, in addition to affecting the recruitment of immature myeloid cells to the tumor site, our data also indicate an additional role for T H 17 cells recruited to the tumor microenvironment in facilitating the activation of MDSCs and their function in establishing a VEGF-independent proangiogenic milieu.
Our findings are consistent with previous reports that IL-17 is required for tumor promotion in preclinical models 8 , including a study that reported the ability of IL-17 to recruit MDSCs, such as CD11b + Gr1 + cells, to the tumor environment to promote tumor growth 39 . Although we did not observe this phenomenon in all tumor models tested, our study demonstrates the importance for IL-17 signaling not only in cell recruitment but also for the function of tumor stroma. Together our findings reinforce the importance of the IL-17-G-CSF-Bv8 axis in mediating VEGF-independent tumor angiogenesis in vivo, although we do not rule out a possible direct proangiogenic contribution of IL-17 ( Supplementary Fig. 8) .
That the resistance of the tumor models used in this study, the EL4 and LLC cell lines, to VEGF blockade is fully independent of VEGF function is also supported by recent findings documenting the resistance of these cell lines to sunitinib and axitinib, two potent US Food and Drug Association-approved small-molecule inhibitors that target the tyrosine kinase activity of VEGF receptors 40 . This class of molecules has been shown to inhibit both paracrine and intracrine VEGF signaling 41, 42 . Thus, intracellular VEGF signaling, which is not blocked by antibodies, is probably not a contributing factor to the refractory phenotype of these tumor models.
Our data parallels recent findings revealing that IL-9 expressed by IL-17-deficient ROR-γ − CD4 + T cells mediates tumor suppression in tumor models similar to those used in our study 43 . In contrast, T H 17 cells have also been associated with tumor suppression and better prognosis in both preclinical models and patient populations 10 . Proposed explanations for these discrepancies broadly suggest a protumor IL-17 effect in immunodeficient mice compared to an antitumor effect in immunocompetent mice 8 . Our findings, however, are inconsistent with an antitumor effect of T H 17 cells in immunocompetent mice, as we documented IL-17-dependent tumor growth and resistance to VEGF blockade in syngeneic tumor models. It is also unlikely that IL-22, a T H 17 cell-derived cytokine, influences stromal function, as IL-22 receptor expression is limited to epithelial cells of the digestive organs, respiratory tract and skin 44 . Our findings in preclinical models of lung and colorectal cancer are consistent with clinical reports that the presence of T H 17 immune infiltrates correlates with worse prognosis and overall survival, whereas their presence correlates with better outcomes in other tumor types, such as ovarian and gastric cancers 10 . These divergent clinical findings highlight the effect of the tumor context in informing the function of immune infiltrates and argue that care is needed in selecting tumor types that might be treated with IL-17-specific antibodies.
Crosstalk between adaptive and innate immunity in mediating tumor resistance to VEGF blockade has not been previously reported. Our studies show that inhibiting T H 17 cells and their paracrine function in the tumor microenvironment substantially enhances the tumor response to VEGF blockade. Further studies will be needed to determine how generalizable these findings are to additional tumor types and whether tumor-infiltrating immune cells could serve as biomarkers for stratifying patients for their responsiveness to VEGF blockade, such as with bevacizumab. It also remains to be established whether IL-17 mediates resistance to targeted therapies other than anti-angiogenic agents. Our findings have the potential to improve the clinical efficacy of VEGF-targeting agents through inhibition of T H 17 cell function.
METHODS
Methods and any associated references are available in the online version of the paper. 
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